Hypertension Clinical Trial
Official title:
A Cluster Randomized Trial to Evaluate Comprehensive Approach to Hypertension Management in Nepal
NCT number | NCT05292469 |
Other study ID # | 399476 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | May 2, 2022 |
Est. completion date | September 2023 |
Hypertension is a global risk factor for cardiovascular diseases. Approximately 80% hypertension burden is in low-and-middle income countries. Hypertension can be managed with antihypertensive medication and following effective lifestyle interventions, however the control rate of hypertension among those on treatment is dismal. In Nepal, a quarter of adult population have hypertension of whom, 44% are unaware of their status, 33% are on treatment, and, only 12% are controlled. A comprehensive intervention strategy for hypertension management has shown promising results in high income countries. Therefore, it is of interest to understand its effectiveness, appropriateness and feasibility in the low income settings such as Nepal. The objective of the trial is to assess the impact on net change in mean systolic blood pressure measured between 7 to 8 months follow-up of a comprehensive intervention which provides personalized counselling on lifestyle modification and medication adherence together with support for regular monitoring of blood pressure at home, compared with a control arm where hypertensive patients have access to routine care only. The investigators are proposing a cluster randomized controlled trial conducted in government health facilities from Budhanilakantha, an urban municipality in the Bagmati Province of Nepal. Trial arms: 1) control (routine hypertension care); 2) Comprehensive approach to hypertension management that includes blood pressure (BP) audit and feedback by physician (nurse and doctor), and patient support to monitor BP, and home based patient care by community health workers to encourage self-monitoring of BP followed by tailored educational counselling on behavioral and lifestyle change. Eligible participants providing consent will be enrolled into the trial by a research assistant who will conduct interviews. Those from the intervention arm will receive the home visits for 6 months. Participants from both arms will provide follow up data in 7 to 8 months.
Status | Recruiting |
Enrollment | 1250 |
Est. completion date | September 2023 |
Est. primary completion date | September 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Hypertension patients (systolic blood pressure 140 mmHg or more and/or diastolic blood pressure 90 mmHg or more on at least two separate visits, or use of antihypertensive medication) - Living in the area served by the participating health facilities Exclusion Criteria: - Pregnancy - Not able or willing to give informed consent, - Critically ill from depilating conditions such as dialysis, cancer, palliative care - Not likely to continue living in the area served by the health facility during trial follow up period (8 months) |
Country | Name | City | State |
---|---|---|---|
Nepal | Institute for Implementation Sciences and Health | Kathmandu |
Lead Sponsor | Collaborator |
---|---|
Norwegian University of Science and Technology | Institute for Implementation Sciences and Health, Kathmandu, Nepal |
Nepal,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean systolic blood pressure (BP) (mmHg) | Net change in mean systolic BP from baseline to follow up | Measured at baseline and follow up between 7 to 8 months after baseline | |
Secondary | Mean diastolic BP (mmHg) | Net change in mean diastolic BP from baseline to follow up | Measured at baseline and follow up between 7 to 8 months after baseline | |
Secondary | Proportion controlling BP (<140/90 mmHg) | Proportion of participants controlling BP (<140/90 mmHg) from baseline to follow up | Measured at baseline and follow up between 7 to 8 months after baseline | |
Secondary | Waist Circumference (cm) | The mean difference in waist circumference measured at baseline and follow up | Measured at baseline and follow up between 7 to 8 months after baseline | |
Secondary | Body weight (Kg) | The mean difference in weight measured at baseline and follow up | Measured at baseline and follow up between 7 to 8 months after baseline | |
Secondary | Diet low in cholesterol, high in fruits and vegetables | The proportion consuming diet low in cholesterol, high in fruits and vegetables in the last 24 hours self reported at baseline and follow up | Reported at baseline and follow up between 7 to 8 months after baseline | |
Secondary | Daily salt intake (<1 teaspoon per day) | The proportion consuming less than 1 teaspoon of salt per day self reported at baseline and follow up | Reported at baseline and follow up between 7 to 8 months after baseline | |
Secondary | Medication adherence | The proportion adhering to prescribed medication in the past two weeks measured at baseline and follow up | Self reported at baseline and follow up between 7 to 8 months after baseline | |
Secondary | Physical activity | The proportion engaged in moderate physical activity (2.5 hours per week) measured at baseline and follow up | Self reported at baseline and follow up between 7 to 8 months after baseline | |
Secondary | Hypertension Knowledge Score | All together 21 hypertension knowledge statement with 12 true false responses and others with multiple responses to create a aggregate score on hypertension Knowledge | Self reported at baseline and follow up between 7 to 8 months after baseline | |
Secondary | Perceived Social Support Scale | Twelve statements on perceived social support with 7 point Likert scale will be used at baseline and endline | Self reported at baseline and follow up between 7 to 8 months after baseline | |
Secondary | Maintaining BP logs | Proportion of trial participants maintaining self BP measurement logs asked during follow up | Self reported at follow up between 7 to 8 months after baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Completed |
NCT03093532 -
A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT05529147 -
The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
|
||
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Recruiting |
NCT05976230 -
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
|
||
Completed |
NCT06008015 -
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05387174 -
Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Recruiting |
NCT05121337 -
Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension
|
N/A | |
Withdrawn |
NCT04922424 -
Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
|
Phase 1 | |
Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
Completed |
NCT05087290 -
LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
|
||
Not yet recruiting |
NCT05038774 -
Educational Intervention for Hypertension Management
|
N/A | |
Completed |
NCT05621694 -
Exploring Oxytocin Response to Meditative Movement
|
N/A | |
Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
Recruiting |
NCT05575453 -
OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure
|
N/A |